Search - tctmd.com

Displaying 41 - 60 of 68

Sort: Relevancy | Date

News Daily News

Ethnic Variations in Lp(a) Concentrations Challenge Current Risk Thresholds

Yael L. Maxwell

January 25, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Caitlin E. Cox

August 15, 2018

News Conference News EAS 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Yael L. Maxwell

May 16, 2018

News Daily News

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Michael O'Riordan

January 09, 2018

News Daily News

Diabetes Remission Possible With Significant Weight Loss: DiRECT

Michael O'Riordan

December 05, 2017

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Conference News ESC 2017

Less Is More? Health Benefits of Fruits, Vegetables, and Legumes Seen at Lower Intake Levels

Michael O'Riordan

August 29, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Conference News ACC 2017

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

A Deadly Diet: Half of US Deaths From Cardiometabolic Causes Linked to Dietary Habits

Michael O'Riordan

March 08, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT

Michael O'Riordan

September 29, 2016

News Conference News ESC 2016

Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD

Todd Neale

September 09, 2016

News Daily News

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Yael L. Maxwell

August 29, 2016

News Daily News

Statins Lower but Don’t Erase the Excess Risk of Coronary Disease and Death in Familial Hypercholesterolemia

Todd Neale

July 12, 2016

News Conference News EAS 2016

Statin-Associated Muscle Symptoms: Real or ‘Artificial,’ Physicians Should Take Time to Manage Patients

Yael L. Maxwell

June 01, 2016

News Conference News EAS 2016

Good Fats, Bad Fats, and Sugar: A ‘Big Picture’ Approach Is Warranted With Diet Interventions for Cardiovascular Disease

Yael L. Maxwell

May 31, 2016

Advertisement

Ethnic Variations in Lp(a) Concentrations Challenge Current Risk Thresholds

TCTMD’s Top 10 Most Popular Stories for November 2018

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Diabetes Remission Possible With Significant Weight Loss: DiRECT

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Less Is More? Health Benefits of Fruits, Vegetables, and Legumes Seen at Lower Intake Levels

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

A Deadly Diet: Half of US Deaths From Cardiometabolic Causes Linked to Dietary Habits

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT

Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Statins Lower but Don’t Erase the Excess Risk of Coronary Disease and Death in Familial Hypercholesterolemia

Statin-Associated Muscle Symptoms: Real or ‘Artificial,’ Physicians Should Take Time to Manage Patients

Good Fats, Bad Fats, and Sugar: A ‘Big Picture’ Approach Is Warranted With Diet Interventions for Cardiovascular Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content